Transforming cancer care at all stages of the disease
AJ Patel
7-year stage IV lung cancer survivor

Transforming cancer care at all stages of the disease

We are dedicated to helping patients at all stages of cancer live longer and healthier, through the power of blood tests and the data they unlock. Today our FDA-approved test helps inform treatment decisions for patients with advanced cancer. Our tests also detect residual and recurrent disease for patients with early-stage cancer, and will soon screen to find cancer at its earliest and most treatable stage.

Learn more
July 20, 2023

Guardant Health receives first commercial payor coverage for Guardant Reveal™ te...

First blood-only liquid biopsy test for molecular residual disease now covered for serial testing in patients with stage II or III...
READ MORE
July 5, 2023

Guardant Health announces reimbursement approval of Guardant360® CDx liquid biop...

Reimbursement supports expanded access to blood-based comprehensive genomic profiling with Guardant360 CDx for patients with adva...
READ MORE
May 31, 2023

Guardant Health to present 17 scientific abstracts highlighting contribution of...

New research further confirms value of interrogating epigenomic signals with Guardant Infinity™ platform to identify novel biomark...
READ MORE
May 17, 2023

Guardant Health Secures Coverage From Major US Commercial Health Insurers for Gu...

With new coverage from Anthem Blue Cross and Blue Shield, Aetna and Humana, Guardant360 CDx/Guardant360 liquid biopsy test now cov...
READ MORE
May 16, 2023

Guardant Health Releases Inaugural ESG Report...

The publication of its inaugural Environmental, Social & Governance (ESG) Report, which provides information related to key ESG co...
READ MORE
May 9, 2023

Guardant Health presents additional information from ECLIPSE study at 2023 Diges...

Shield ™ blood test achieved overall 83% sensitivity and 90% specificity and demonstrated early-stage detection in range with oth...
READ MORE
See all press releases
Precision oncology

Delivering on the promise for patients

Precision oncology is redefining cancer care by driving a more personalized and data-driven approach that improves on traditional standards of care. From using biomarkers to inform treatment in advanced cancer, to using circulating tumor DNA to not only assess response to treatment, but detect signs of remaining cancer and even identify the earliest signs of cancer, precision oncology is helping patients across all stages of the disease.

Learn more
Products

Blood tests are at the core of our mission

Blood is at the center of transforming cancer care by holding insights that can improve clinical outcomes. Over 300,000 of our blood tests have been performed by 12,000 doctors to date. Our commercially available tests help inform treatment decisions for patients with advanced cancer, monitor treatment response, detect residual and recurrent disease in patients with early-stage cancer, and soon may help screen for cancer before symptoms appear. Our products also help pharmaceutical companies develop the next generation of cancer therapies.

    • “Our focus is always on what will have the greatest impact on patients.”
    Helmy Eltoukhy, co-CEO
    Careers

    Together we can help conquer cancer

    When you join our team, you become part of a mission that impacts so many personally: conquering cancer with data. We are passionate about serving patients and their families through the power of blood and the life-changing information it holds. Guardant Health is hiring bright minds in diverse fields to solve some of the most profound challenges in human health today.

    Learn more